BioMarin Pharmaceutical Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 766.2M | 874.6M | 776.1M | 825.4M | 745.1M | 747.3M | 745.7M | 712.0M |
| Cost of Goods Sold | 195.0M | 295.1M | 140.1M | 150.1M | 151.6M | 136.1M | 188.5M | 130.5M |
| Gross Profit | 571.2M | 579.5M | 636.0M | 675.3M | 593.6M | 611.2M | 557.3M | 581.6M |
| R&D Expenses | 178.8M | 192.4M | 409.5M | 161.3M | 158.7M | 173.5M | 184.9M | 183.8M |
| Operating Expenses | 441.6M | 500.1M | 682.7M | 398.4M | 369.7M | 449.8M | 443.4M | 461.1M |
| Operating Income | 129.6M | 79.4M | -46.7M | 276.9M | 223.9M | 161.4M | 113.9M | 120.5M |
| Other Income / Gains | 11.6M | -106.5M | 20.4M | 21.0M | 14.2M | 8.2M | 20.5M | 11.7M |
| Net Income | 105.5M | -46.6M | -30.7M | 240.5M | 185.7M | 124.9M | 106.1M | 107.2M |
| EPS (Diluted) | 0.55 | -0.24 | -0.16 | 1.25 | 0.97 | 0.66 | 0.57 | 0.56 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.746 | 0.663 | 0.82 | 0.818 | 0.797 | 0.818 | 0.747 | 0.817 |
| General And Administrative Expenses | 133.4M | 802.1M | 137.1M | 110.2M | 103.6M | 141.0M | 144.6M | 140.2M |
| Selling And Marketing Expenses | 124.9M | 0 | 131.3M | 122.1M | 102.5M | 125.6M | 108.9M | 122.8M |
| Selling General And Administrative Expenses | 258.3M | 802.1M | 268.4M | 232.3M | 206.1M | 266.6M | 253.5M | 263.0M |
| Other Expenses | 4.5M | -494.4M | 4.8M | 4.8M | 4.9M | 9.7M | 5.0M | 14.3M |
| Cost And Expenses | 636.6M | 795.2M | 822.8M | 548.5M | 521.3M | 585.9M | 631.8M | 591.6M |
| Interest Income | 22.6M | 19.2M | 17.9M | 18.8M | 19.0M | 17.7M | 18.1M | 19.8M |
| Interest Expense | 15.0M | 2.8M | 2.6M | 2.7M | 2.9M | 2.6M | 3.0M | 3.6M |
| Depreciation And Amortization | 16.4M | 20.4M | 18.5M | 18.6M | 22.1M | 23.6M | 19.0M | 26.5M |
| Ebitda | 172.6M | -3.9M | -5.3M | 319.1M | 263.0M | 195.5M | 156.4M | 162.2M |
| Ebitdaratio | 0.225 | -0.005 | -0.007 | 0.387 | 0.353 | 0.262 | 0.21 | 0.228 |
| Operating Income Ratio | 0.169 | 0.091 | -0.06 | 0.335 | 0.30 | 0.216 | 0.153 | 0.169 |
| Income Before Tax | 141.2M | -27.2M | -26.3M | 297.9M | 238.1M | 169.6M | 134.4M | 132.1M |
| Income Before Tax Ratio | 0.184 | -0.031 | -0.034 | 0.361 | 0.32 | 0.227 | 0.18 | 0.186 |
| Income Tax Expense | 35.7M | 19.4M | 4.4M | 57.3M | 52.4M | 44.7M | 28.4M | 25.0M |
| Net Income Ratio | 0.138 | -0.053 | -0.04 | 0.291 | 0.249 | 0.167 | 0.142 | 0.151 |
| Epsdiluted | 0.54 | -0.22 | -0.16 | 1.23 | 0.95 | 0.64 | 0.55 | 0.55 |
| Weighted Average Shs Out | 192.5M | 191.8M | 192.0M | 191.4M | 191.0M | 190.7M | 190.4M | 190.1M |
| Weighted Average Shs Out Dil | 197.7M | 197.4M | 192.0M | 196.6M | 196.5M | 196.6M | 197.1M | 200.5M |